phase ii trial of pembrolizumab and cabozantinib in hnscc
Published 1 year ago • 142 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
0:54
phase ib/ii trial of 177lu-girentuximab with cabozantinib and nivolumab in clear cell rcc
-
1:52
safety of bca101, an egfr/tgfβ inhibitor, with pembrolizumab in hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
3:29
emerging roles of nivolumab and cabozantinib for renal cell carcinoma
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
3:54
papmet2: cabozantinib with or without atezolizumab in prcc
-
2:26
sd-101 plus pembrolizumab for hnscc
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
6:02
ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
-
5:34
pembrolizumab for recurrent hnscc
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
1:43
understanding variant histologies in urothelial carcinoma: io and cabozantinib's potential
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
2:00
durvalumab plus danvatirsen for r/m hnscc: exciting scores data
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
4:03
phase i/ii trial of zenocutuzumab for tumors with nrg1 fusions